Previous 10 | Next 10 |
- MAVIRET ™ is now available as a shorter, 8-week, once-daily option for treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT)1, 2, 4, 5 and 6 - Marketing authorization is supported by 97.9 percent cure * rate across this...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 20...
EDP-514 HBV Lead Asset Granted Fast Track Designation from FDA Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has init...
Market Assessment Enanta ( ENTA ) is a small cap ($1.63B) biopharma with a focus on developing innovative therapeutics for viral infections and liver diseases. Enanta gained clinical and investor prominence with the approval of the HCV therapeutics, glecaprevir and paritaprevir, commercializ...
Enata Pharmaceuticals (NASDAQ: ENTA ) is up 6.8% premarket after the company notes EDP-938 cut the amount of virus detected in the body in a study of healthy adults infected with respiratory syncytial virus. More news on: Enanta Pharmaceuticals, Inc., Healthcare stocks news, Stocks on ...
EDP-938 achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo Conference call and webcast to discuss the data at 8:30 a.m. ET today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and...
Market Assessment Enanta ( ENTA ) is a commercial-stage small market cap ($1.8B) biopharma that has established itself as an innovator of effective therapeutics for the viral liver disease, HCV infection, through the approval of paritaprevir and glecaprevir. Its license agreement with Ab...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fires...
Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Conference Call May 07, 2019 4:30 PM ET Company Participants Carol Miceli - Director of Investor Relations Jay Luly - President & Chief Executive Officer Paul Mellett - Chief Financial Officer Conference Call Participant...
Enanta Pharma (NASDAQ: ENTA ): Q2 GAAP EPS of $0.20 beats by $0.29 . More news on: Enanta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Enanta Pharmaceuticals Inc. Company Name:
ENTA Stock Symbol:
NASDAQ Market:
Enanta Pharmaceuticals Inc. Website:
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strate...
2024-05-10 16:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Nuwellis Inc. (NUWE) rose 60.3% to $0.2741 on volume of 66,284,094 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 21.1% to $0.05 on volume of 64,247,106 shares Clearmind Medicine Inc. (CMND) rose 37.6% to $1.61 on volume ...